Ardelyx, Inc. (ARDX) - Cash on Hand per Share

Symbol and logo of brand ardelyx.com (ARDX)

Ardelyx, Inc. (ARDX) generates revenue through the supply of innovative medications for dialysis and IBS patients via health insurance systems. The free cash flow per share trend confirms this growth, where 1.13 reflects the baseline level of the metric. The business model relies on CMO contract manufacturing, while a steady cash flow ensures the coverage of all operating expenses and capital expenditures.

ARDX - Ardelyx, Inc. Cash per Single Share over the range 07/04/2022 - 11/20/2026

Analytical breakdowns for Ardelyx (ARDX)

- current price and projected stock value:
- market capitalization indicators:
- cash and cash flow data:
Summary company analysis:Ardelyx, Inc.
Product sample of ardelyx.com

To objectively evaluate the issuer, it is critical for the manager to understand the volume of liquid assets available per ordinary share, which allows for the identification of hidden business value and undercapitalization risks. The current cash per share stands at 1.13, which, given the non-cyclical nature of the pharmaceutical market, provides Ardelyx, Inc. (ARDX) with high resilience to macro shocks due to stable demand for kidney disease medications.